Drug Profile
Research programme: liposomal RNAi therapeutics - Arrowhead Pharmaceuticals
Latest Information Update: 04 Apr 2018
Price :
$50
*
At a glance
- Originator Arrowhead Research Corporation; Roche
- Developer Arrowhead Pharmaceuticals
- Class Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified